Federal Register / Vol. 72, No. 83 / Tuesday, May 1, 2007 / Notices 23835 

occupation and its duration, (4) 

Background information on the school 

or Organization/Community. Frequency 

of Response: This project will be 

conducted once. Affected Public: School 

personnel, and Community Leaders who 

have requested the NGBTS materials. 

Type of Respondent: School personnel, 

and Community Leaders who have 

requested the NGBTS materials from the 

NIDA site. Estimated Total Annual 

Number of Respondents: 400. Estimated 

Number of Responses per Respondent: 

1. Average Burden Hours per Response: 

.08. Estimated Total Annual Burden 

Hours Requested: 96.0. There are no 

Capital Costs to report. There are no 

Operating or Maintenance Costs to 

report. The estimated annualized 

burden is summarized below. 

Type of respondents Number of 

respondents 

Frequency of 

response 

Average 

burden hours 

per response 

Estimated total 

burden hours 

requested 

Requestors—School Personnel ....................................................................... 600 1 0.08 48 

Requestors—Community Leaders ................................................................... 600 1 0.08 48 

Total .......................................................................................................... 1200 ........................ ........................ 96 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(2) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (3) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, New Executive 

Office Building, Room 10235, 

Washington, DC 20503, Attention: Desk 

Officer for NIH. To request more 

information on the proposed project or 

to obtain a copy of the information 

collection plans, contact Brian Marquis, 

Project Officer, National Institute on 

Drug Abuse, 6001 Executive Boulevard, 

Room 5216, Bethesda, MD 20892, or call 

non-toll-free number 301–443–1124; fax 

301–443–7397; or by e-mail to 

bmarquis@nida.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

Dated: April 21, 2007. 

Donna Jones, 

Budget Officer & Acting Associate Director 

for Management, National Institute on Drug 

Abuse. 

[FR Doc. E7–8293 Filed 4–30–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

New High-Throughput and 

Bioinformatic Tools To Identify and 

Use Genomic DNA Sequence 

Dimorphisms (Indels) 

Description of Technology: This 

invention describes new methods to 

identify genomic DNA sequence 

dimorphisms called indels and to 

determine their biological 

consequences. ‘‘Indels’’ refers to large 

insertions and deletions, a form of 

variation in DNA sequences, that can 

cause genotypic and phenotypic 

differences between cells, tissues, 

individuals, populations or species. The 

technology describes new bioinformatic 

tools and high-throughput methods to 

identify such dimorphisms. 

Additionally, the technology provides 

new assays to distinguish genomic 

sequences by genotyping, understand 

the role of such indels in altering gene 

expression, for example in disease 

pathogenesis, develop new models for 

variation in genomes and in gene 

expression, and improve methods for 

the molecular diagnosis and treatment 

of disease. 

Applications: 

1. A new bioinformatics software tool 

that can easily identify dimorphisms 

and can help create a searchable 

database and graphical interface 

containing sites of dimorphisms and 

information regarding functional effects 

of dimorphisms. 

2. Low cost, high-throughput PCR 

based methods to identify dimorphic 

repetitive elements from any eukaryotic 

genome including individual tissue 

specimens. 

3. Methods to determine functional 

consequences of dimorphisms (indels). 

Development Status: 

1. Bioinformatics software tools are 

ready for use. 

2. High-throughput PCR methods 

have been validated. 

3. Annotated mouse genes whose 

expression is altered by dimorphic 

indels have been identified. 

Inventors: David E. Symer et al. (NCI). 

Relevant Publications: 

1. Manuscripts relating to this 

invention are under preparation and 

will be available once accepted for 

publication. 

2. RE Mills et al. An initial map of 

insertion and deletion (INDEL) variation 

in the human genome. Genome Res. 

2006 Sep;16(9):1182–1190. 

Patent Status: U.S. Provisional 

Application No. 60/841,089 filed 29 

Aug 2006 (HHS Reference No. E–301– 

2006/0-US–01) 

Licensing Status: This technology is 

available for licensing under an 


rmajette on DSK2TPTVN1PROD with MISCELLANEOUS
23836 Federal Register / Vol. 72, No. 83 / Tuesday, May 1, 2007 / Notices 

exclusive or non-exclusive patent 

license. 

Licensing Contact: Michelle Booden, 

PhD; 301/451–7337; 

boodenm@mail.nih.gov 

Collaborative Research Opportunity: 

The National Cancer Institute, Center for 

Cancer Research, Mouse Cancer 

Genetics Program is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize identification and use of 

such genomic DNA sequence insertion/ 

deletion dimorphisms (indels). Please 

contact John D. Hewes, PhD at 301/435– 

3121 or hewesj@mail.nih.gov for more 

information. 

Self-Assembling Nanoparticles 

Composed of Transmembrane Peptides 

and Their Application for Specific 

Intra-Tumor Delivery of Anti-Cancer 

Drugs 

Description of Technology: The 

current invention discloses peptide 

based nanoparticles as an alternative to 

liposomes. The nanoparticles have a 

diameter of 8–10 nm and are much 

smaller than a liposome thus providing 

better tumor penetration. Peptides 

corresponding to transmembrane 

domains of a number of integral 

membrane proteins have been 

discovered that spontaneously selfassemble in aqueous solutions into 

stable and remarkably uniform 

nanoparticles. The nanoparticles of the 

current invention are fully synthetic, 

and their surfaces can be functionalized 

with ligands that provide specific 

binding to cell surface receptors 

overexpressed on tumor cells. Thus, 

they are even more specific for tumor 

targeting. 

Nanoparticles constructed from 

transmembrane domains of certain 

receptors and transporters have 

biological activity of their own and 

inhibit metastasis or drug resistance 

thus sensitizing tumors to therapy. 

Hydrophobic drugs can be easily 

entrapped inside the nanoparticles, 

which not only solve the problem of 

drug insolubility under physiological 

conditions, but also generate a form of 

a drug that concentrates in tumors due 

to enhanced permeability and retention 

(EPR) effects. 

Applications and Modality: 

1. Self-assembling nano-particles as 

an alternative to liposomes, inorganic, 

dendrimeric or polymeric nanoparticles. 

2. Nanoparticles have biological 

activity of their own and can inhibit 

metastasis (CXCR4 receptor antagonists) 

or drug resistance (inhibitors of ABCG2 

transporter and p-glycoprotein) thus 

sensitizing tumors to therapy. 

Advantages: 

1. The nanoparticles are superior in 

stability, uniformity, ease and 

reproducibility of preparation compared 

to conventional liposomes, are much 

more uniform and less toxic than 

inorganic, polymeric or dendrimeric 

nanoparticles. 

2. The nanoparticles are much smaller 

than a liposome thus providing better 

tumor penetration. 

3. Synthetic nanoparticles can be 

easily coated with receptor ligands and 

loaded with hydrophobic drugs for more 

specific tumor targeting. 

Market: Drug delivery remains one of 

the biggest challenges for the 

pharmaceutical industry. Nearly all 

therapeutics currently on the market are 

delivered in a non-specific manner to 

the whole body, and this results in 

unintentional side effects. The Food and 

Drug Administration (FDA) has created 

a new class of therapeutic products 

using nanoparticulate drug delivery 

system. In 2005, the first 

nanoparticulate drug delivery product, 

Abraxane, for the treatment of breast 

cancer, was launched. The worldwide 

R&D investment in nanotechnology 

research and development in 2004 from 

both public and private sectors was an 

estimated $US8.4 billion, 15% of which 

will be focused on nanobiotechnology. 

Development Status: The technology 

is in the pre-clinical stage of 

development. 

Inventors: Nadya I. Tarasova et al. 

(NCI). 

Related Publication: NI Tarasova et al. 

Transmembrane inhibitors of Pglycoprotein, an ABC transporter. J Med 

Chem. 2005 Jun 2;48(11):3768–3775. 

Patent Status: U.S. Provisional 

Application No. 60/864,665 filed 07 

Nov 2006, entitled ‘‘Self-Assembling 

Nanoparticles Composed of 

Transmembrane Peptides and Their 

Application for Specific Intra-Tumor 

Delivery of Anti-Cancer Drugs’’ (HHS 

Reference No. E–256–2006/0–US–01). 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Collaborative Research Opportunity: 

The NCI Center for Cancer Research is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

self-assembling nanoparticles with 

intrinsic anti-tumor activity. Please 

contact John D. Hewes, PhD at 301–435– 

3121 or hewesj@mail.nih.gov for more 

information. 

Sipa-Gene and Sipa-1 Inhibitor for the 

Diagnosis and Treatment of Metastatic 

Cancer 

Market Opportunity: No screening 

markers are currently available in the 

market that can diagnose early 

metastasis, which causes majority of 

cancer related deaths. Opportunity for 

new diagnostic and therapeutic 

technologies exists as personalized 

medicine is taking a major role in the 

clinical management of cancer. This 

invention can provide the much needed 

new diagnostic marker for predicting 

early metastasis as well as a new 

therapy targeting metastasis causing 

factors. 

Description of Technology: This 

technology relates to methods and 

compositions of a new gene Sipa-1 that 

can identify and treat metastatic cancer. 

The inventors have identified the Sipa1 gene as a possible metastasis 

modifying gene. Further analyses 

revealed that Sipa-1 expression levels 

correlate with metastasis. Inhibitors that 

modulate the Sipa-1 expression and 

reduce metastasis in animal models 

have been identified. Additionally, 

single nucleotide polymorphisms 

(SNPs) present in the mouse Sipa-1 gene 

have been identified that, if also present 

in humans, could serve as the basis for 

diagnosing cancer and metastasis. 

Applications and Modality: Method 

for diagnosing early onset of metastasis 

with Sipa-1; Sipa-1 as a new therapeutic 

target for treatment of metastatic cancer. 

Advantages: Simple PCR based assay 

for detecting single nucleotide 

polymorphisms (SNPs) within the Sipa1 gene; Inhibitors of Sipa-1 are known 

in the art, they can be easily screened 

from existing small molecule libraries. 

Current Development Status: 

1. The technology is currently in the 

pre-clinical stage of development. 

2. Proof of concept results show that 

inhibition of Sipa-1 reduces metastasis 

in mouse models. 

3. Laboratory data shows single 

nucleotide polymorphisms (SNPs) 

within the Sipa-1 gene linked to 

metastatic disease. 

Inventors: Kent Hunter et al. (NCI). 

Publications: 

1. PCT Publication No. WO 

2006084027, published October 8, 2006. 

2. YG Park et al. Sipa1 is a candidate 

for underlying the metastasis efficiency 

modifier locus Mtes1. Nat Genet. 2005 

Oct;37(10):1055–1062. Epub 2005 Sep 4. 

3. NP Crawford et al. Germline 

polymorphisms in SIPA-1 are associated 

with metastasis and other indicators of 

poor prognosis in breast cancer. Breast 

Cancer Res. 2006;8(2):R16. Epub 2006 

Mar 21. 


rmajette on DSK2TPTVN1PROD with MISCELLANEOUS
Federal Register / Vol. 72, No. 83 / Tuesday, May 1, 2007 / Notices 23837 

Patent Status: U.S. Provisional 

Application No. 60/649,365 filed 02 Feb 

2005 (HHS Reference No. E–082–2005/ 

0–US–01); PCT Application No. PCT/ 

US2006/003672 filed February 2, 2006 

(HHS Reference No. E–082–2005/2– 

PCT–01). 

Related Technology: U.S. Provisional 

Application No. 60/695,024 filed 29 Jun 

2005 (HHS Reference No. E–216–2005/ 

0–US–01). 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Mojdeh Bahar, J.D.; 

301/435–2950; baharm@mail.nih.gov. 

Dated: April 20, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–8288 Filed 4–30–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Amended 

Notice of Meeting 

Notice hereby given of a change in the 

meeting of the Subcommittee G— 

Education, June 26, 2007, 8 a.m. to June 

27, 2007, 5 p.m., Gaithersburg Marriott 

Washingtonian Center, 204 Boardwalk 

Place, Gaithersburg, MD 20878 which 

was published in the Federal Register 

on April 16, 2007, 72FR19006. 

The meeting has been rescheduled to 

a one day meeting that will occur on 

June 26, 2007. The meeting is closed to 

the public. 

Dated: April 23, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2131 Filed 4–30–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the Sleep 

Disorders Research Advisory Board. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Sleep Disorders 

Research Advisory Board. 

Date: June 19, 2007. 

Time: 11 a.m. to 3 p.m. 

Agenda: To discuss sleep research, 

education priorities and programs. Please 

Note: Individuals who have access to the 

World Wide Web can participate by logging 

into the following URL https:// 

webmeeting.nih.gov/sdrabjune07/ at the time 

of the meeting. Also, there will be a 

conference room available for public who do 

not have access to the World Wide Web. 

Place: National Institutes of Health, 

Rockledge One, 6705 Rockledge Drive, 

Conference Room 8111, Bethesda, MD 20817, 

(Virtual Meeting). 

Contact Person: Michael J. Twery, PhD, 

Director, National Center on Sleep Disorders 

Research, Division of Lung Diseases, National 

Heart, Lung, and Blood Institute, National 

Institutes of Health, 6701 Rockledge Drive, 

Suite 10038, Bethesda, MD 20892–7952, 301– 

435–0199, twerym@nhlbi.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nhlbi.nih.gov/meetings/index.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: April 23, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2130 Filed 4–30–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property as such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel, 

NIMH Mood Disorder Research Review. 

Date: May 4, 2007. 

Time: 11 a.m. to 11:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Christopher S. Sarampote, 

PhD, Scientific Review Administrator, 

Division of Extramural Activities, National 

Institute of Mental Health, NIH, 

Neuroscience Center, 6001 Executive Blvd., 

Room 6148, MSC 9608, Bethesda, MD 20892, 

301–443–1959, csarampo@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: April 19, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2123 Filed 4–30–07; 8:45 am] 

BILLING CODE 4140–07–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Nursing Research; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Council for Nursing 

Research. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 


rmajette on DSK2TPTVN1PROD with MISCELLANEOUS